News

In this article, we recap a timeline of recent federal agency changes to routine COVID-19 vaccination intended for the pediatric population.

With the new drug application accepted with priority review, the FDA has assigned a date of November 20, 2025, to complete its review for potential approval.

The hyperpolarized contrast agent for oral inhalation can now be used in patients 6 years and older, lowering the approved indication from 12 years of age.

Colleen Sloan, PA-C, RDN, shares some practical tips for providers and caregivers to help keep children hydrated during the summer.

Colleen Sloan, PA-C, RDN, highlights the connection between poor dietary patterns and mental health challenges in children, and offers nutrient-focused solutions.

Federal health agencies have adjusted COVID vaccine guidance, potentially changing eligibility and access for pediatric patients. Experts respond in this article.

Victor Carrion, MD, explains how providers can recognize the signs of accumulated stress in children and support recovery through education and connection.

New phase 3b durability data revealed nirsevimab reduced RSV hospitalizations in infants by 82.7% through 180 days vs no intervention.

The decision makes hydrocortisone oral solution (Khindivi; Eton Pharmaceuticals) the only FDA-approved oral formulation of hydrocortisone.

Can you diagnose this patient?

Infants and toddlers with infection history were more likely to have trouble sleeping, while preschool-aged children experienced daytime tiredness.

"These younger individuals are at much higher risk of getting disease and having complications," said Tina Tan, MD, FIDSA, FPIDS, FAAP.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on the May 2025 cover story of Contemporary Pediatrics.

RFK Jr. stated he "couldn't be more pleased" to announce that COVID-19 vaccination among healthy children and pregnant women has been removed from CDC's immunization schedule.

The approved indication now includes children down to 6 weeks of age to protect against invasive meningococcal disease via serogroups A, C, W, and Y.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

A recently published study found sharp increase in the use of nicotine pouches among US high school students, with usage nearly doubling from 2023 to 2024.

Our editor-in-chief Tina Tan, MD, reacts to a new FDA COVID-19 framework that will limit eligibility for seasonal vaccination in pediatrics.

Roflumilast foam 0.3% trial investigator Jennifer Soung, MD, joined us to discuss the importance of this newly FDA-approved topical treatment for patients aged 12 years or older with scalp and body psoriasis.

The once-daily, steroid-free topical is now approved to treat plaque psoriasis of the scalp and body in patients aged 12 years and older.

“These findings provide evidence that social media may be contributing to the development of depressive symptoms,” said Jason M. Nagata, MD, MSc.

Victor Carrion, MD, emphasizes how pediatricians can monitor and support mental health in youth while navigating limited access to specialized care.

The expanded indication follows original approval in August 2018 for use in previously-treated patients 12 years and older.

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.

Most videos on TikTok regarding hormonal contraception were misleading, according to a study presented at the 2025 ACOG Annual Clinical and Scientific Meeting.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Albuterol-budesonide (Airsupra; AstraZeneca) resulted in a 47% reduction in severe exacerbations in mild asthma vs albuterol alone.

NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes.